bcastle – Page 18 – Thought Leader Select

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three

Key Opinion Leaders Help to Foster Robust, Viable Pharmaceutical and Biotechnology Pipelines Imagine a world where pharmaceutical and biotechnology companies developed therapies without input from KOLs at various stages of product discovery and development. The results would be far fewer treatments available, greater risks for unwanted side effects and potentially, a larger number of unnecessary …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three Read More »

Thought Leader Select announces neurology key opinion leader work for top-20 global pharmaceutical company

Uncategorized / By bcastle

The pharmaceutical company chose Thought Leader Select over traditional influence-mapping firms to begin identifying and profiling 200 global KOLs in neurology. Thought Leader Select’s exclusive “deep-profiling” research methodology eclipses more limited approaches that rely on subjective data gleaned from surveys with low statistical efficacy.

PharmExec's 2010 Forecast Reflected in Thought Leader Select's Current Projects

Uncategorized / By bcastle

While 2010 continues to be a challenging year for the pharmaceutical industry as a whole, certain targeted areas of development continue to gain attention from the industry. In PharmExec’s 2010 forecast,Alexandra Kibble predicted continued focus on the following therapeutic areas: cardiovascular, oncology, and anti-infectives. Kibble also predicted a rise in pipeline development of treatments for …

PharmExec's 2010 Forecast Reflected in Thought Leader Select's Current Projects Read More »

Thought Leader Select begins key research and advisory services for seven global pharmaceutical companies

Uncategorized / By bcastle

New press release out today, celebrating the tremendous efforts of our business development and research teams. FOR IMMEDIATE RELEASE March 9, 2009 (CHAPEL HILL, NC) Thought Leader Select, a company dedicated to delivering solutions for better engagement and more sophisticated deployment of key opinion leaders (KOLs) for the pharmaceutical and biotechnology industries, announces on-going research …

Thought Leader Select begins key research and advisory services for seven global pharmaceutical companies Read More »

CME Demanding Greater Compliance through Faculty Selection Criteria Consistency

1 Comment / Uncategorized / By bcastle

With heightened scrutiny on the objectivity of Continuing Medical Education meetings in recent years, pharmaceutical companies have placed more emphasis on understanding skills and experiences of physician Thought Leaders who may serve as CME faculty. In addition to publishing grant databases which outline monies paid to speakers, CME faculty and other advisors, leading companies are …

CME Demanding Greater Compliance through Faculty Selection Criteria Consistency Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two

Uncategorized / By bcastle

KOLs Provide the “Voice of the Patient” for Life-changing Discoveries According to the Pharmaceutical Research and Manufacturers of America (PhRMA—(http://www.phrma.org/), “Only one of every 10,000 potential medicines investigated by America’s research-based pharmaceutical companies makes it through the research and development pipeline and is approved for patient use by the United States Food and Drug Administration.” …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two Read More »

Industry Contraction Spurs New Partnership Opportunities

Uncategorized / By bcastle

According to a February 2010 article in Outsourcing-Pharma.com, pharmaceutical companies will continue to outsource more of their business to single-service providers. To capture more business, CROs will merge or focus on niche opportunities. Thought Leader Select, a research firm providing sophisticated KOL deployment strategies to the pharma and biotech industries, has developed a unique opportunity …

Industry Contraction Spurs New Partnership Opportunities Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One

Uncategorized / By bcastle

Now more than ever, pharmaceutical companies’ relationships with physician thought leaders, also known as key opinion leaders (KOLs), are under intense scrutiny. Industry ethicists and watchdogs alike have speculated on the objectivity of medical education presentations and other aspects of KOL involvement during the marketing of new drug therapies. However, the truth is that physician …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One Read More »

Thought Leader Select Part of a New Wave of Pharma Partners

Uncategorized / By bcastle

An interesting article popped up this week in PharmaLive’s Product Marketing Weekly. Highlighting a new wave of external partners defining Pharma 3.0, the article focused on the effects of downsizing in the industry, and how pharmaceutical companies, now more than ever, are turning to external partners for non-core business functions. At Thought Leader Select, we …

Thought Leader Select Part of a New Wave of Pharma Partners Read More »

The Numbers Don't Lie: The Global Impact of Thought Leader Select

Uncategorized / By bcastle

Since 2005, Thought Leader Select has profiled over 4800 key opinion leaders and over 300 centers of excellence in the field of healthcare. The scope of our 72 completed research projects spans four continents—North America, Europe, Africa, and Asia. We have covered thought leaders in 12 therapeutic areas and over 33 disease states for the …

The Numbers Don't Lie: The Global Impact of Thought Leader Select Read More »